Open an account

Personalis

PSNL · NASDAQ

$15.94+$0.06 (+0.38%)TodayMarket closed ·
Prev close $15.88

About PSNL

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 260 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

Employees
260
Headquarters
Fremont, California
Listed
Jun 20, 2019
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
personalis.com

PSNL key statistics

Market cap
1.70B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.21M
Volume
2.38M
Open price
$15.94
High today
$16.00
Low today
$15.85
52 Week high
$18.89
52 Week low
$4.96

Personalis (PSNL) at a glance

Personalis (PSNL) last traded at $15.94, with a market cap of 1.70B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $15.85 and $16.00. The current price is 0.6% above the day's low and 0.4% below its high.

Volume so far is 2.38M shares, in line with the average of 2.21M shares a day.

Over the past year Personalis has ranged from $4.96 to $18.89, and now sits 79% of the way up that range.

Personalis met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.30 per share against an estimate of -$0.2651.

The average analyst price target is $15.75, 1.2% below the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 6 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 6 analystsAvg $15.75
Low
$13.13
Now
$15.94
High
$17.06

PSNL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 17.1% on average.

  1. Q3 FY24: reported -$0.64 per share against an estimate of -$0.357
  2. Q4 FY24: reported -$0.23 per share against an estimate of -$0.2907
  3. Q1 FY25: reported -$0.18 per share against an estimate of -$0.2521
  4. Q2 FY25: reported -$0.23 per share against an estimate of -$0.2486
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.2842
  6. Q4 FY25: reported -$0.26 per share against an estimate of -$0.299
  7. Q1 FY26: reported -$0.29 per share against an estimate of -$0.2751
  8. Q2 FY26: reported -$0.30 per share against an estimate of -$0.2651

PSNL news

  • Press releaseBusiness Wire

    Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

  • Vandana Singh

    Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

  • Press releasePRNewswire

    Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?

  • Vandana Singh

    What’s Going On With Tempus AI Stock on Monday?

  • Piero Cingari

    Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

  • Press releaseBusiness Wire

    Personalis Reports Second Quarter Results and Recent Highlights

  • Press releasePRNewswire

    Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?

Similar companies

Companies in the same industry as Personalis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.